Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE6671) than lymphokine activated killer cells from peripheral blood

Seok Gu Kang, Chung Hun Ryu, Sin Soo Jeun, Chun Kun Park, Hyung Jin Shin, Jong Hyun Kim, Moon Chan Kim, Joon Ki Kang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objects: The aims of this study were to assess the cytotoxic capability of lymphokine-activated killer (LAK) cells from umbilical cord blood (UCB), to compare them with those of peripheral blood (PB)-derived cells against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671), and to identify which mechanism and genes were involved in cytotoxicity. Methods: The effector cells were generated by interleukin-2 from UCB and PB. The antitumor property of effector cells against the target cells (U87, TE671) were estimated using a visual survival cell assay. The mixed target and effector (UCB) cells were analyzed for whether DNA fragmentation was present or not. Reverse transcription polymerase chain reaction analysis was then performed to estimate the statement of the perforin and FasL genes in activated and inactivated cells from UCB. Results: The higher in vitro antitumor properties of the LAK cells from UCB were observed in comparison to the LAK cells from PB against the U87 and the TE671 (p<0.05). Apoptosis may be one of the lysis mechanisms of target cells by the LAK cells from UCB. The contributing genes could be FasL and perforin. Conclusions: This study suggests that UCB may be used as a source of LAK cells in adults and children suffering from anaplastic astrocytoma or medulloblastoma.

Original languageEnglish
Pages (from-to)154-162
Number of pages9
JournalChild's Nervous System
Volume20
Issue number3
DOIs
Publication statusPublished - 2004 Mar 1

Fingerprint

Lymphokine-Activated Killer Cells
Medulloblastoma
Astrocytoma
Fetal Blood
Cell Line
Perforin
Blood Cells
Genes
DNA Fragmentation
Reverse Transcription
Interleukin-2
Cell Survival
Apoptosis
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

@article{a78c55c9426b436f9a8397711a800bbd,
title = "Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE6671) than lymphokine activated killer cells from peripheral blood",
abstract = "Objects: The aims of this study were to assess the cytotoxic capability of lymphokine-activated killer (LAK) cells from umbilical cord blood (UCB), to compare them with those of peripheral blood (PB)-derived cells against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671), and to identify which mechanism and genes were involved in cytotoxicity. Methods: The effector cells were generated by interleukin-2 from UCB and PB. The antitumor property of effector cells against the target cells (U87, TE671) were estimated using a visual survival cell assay. The mixed target and effector (UCB) cells were analyzed for whether DNA fragmentation was present or not. Reverse transcription polymerase chain reaction analysis was then performed to estimate the statement of the perforin and FasL genes in activated and inactivated cells from UCB. Results: The higher in vitro antitumor properties of the LAK cells from UCB were observed in comparison to the LAK cells from PB against the U87 and the TE671 (p<0.05). Apoptosis may be one of the lysis mechanisms of target cells by the LAK cells from UCB. The contributing genes could be FasL and perforin. Conclusions: This study suggests that UCB may be used as a source of LAK cells in adults and children suffering from anaplastic astrocytoma or medulloblastoma.",
author = "Kang, {Seok Gu} and Ryu, {Chung Hun} and Jeun, {Sin Soo} and Park, {Chun Kun} and Shin, {Hyung Jin} and Kim, {Jong Hyun} and Kim, {Moon Chan} and Kang, {Joon Ki}",
year = "2004",
month = "3",
day = "1",
doi = "10.1007/s00381-003-0898-7",
language = "English",
volume = "20",
pages = "154--162",
journal = "Child's Nervous System",
issn = "0256-7040",
publisher = "Springer Verlag",
number = "3",

}

Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE6671) than lymphokine activated killer cells from peripheral blood. / Kang, Seok Gu; Ryu, Chung Hun; Jeun, Sin Soo; Park, Chun Kun; Shin, Hyung Jin; Kim, Jong Hyun; Kim, Moon Chan; Kang, Joon Ki.

In: Child's Nervous System, Vol. 20, No. 3, 01.03.2004, p. 154-162.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE6671) than lymphokine activated killer cells from peripheral blood

AU - Kang, Seok Gu

AU - Ryu, Chung Hun

AU - Jeun, Sin Soo

AU - Park, Chun Kun

AU - Shin, Hyung Jin

AU - Kim, Jong Hyun

AU - Kim, Moon Chan

AU - Kang, Joon Ki

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Objects: The aims of this study were to assess the cytotoxic capability of lymphokine-activated killer (LAK) cells from umbilical cord blood (UCB), to compare them with those of peripheral blood (PB)-derived cells against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671), and to identify which mechanism and genes were involved in cytotoxicity. Methods: The effector cells were generated by interleukin-2 from UCB and PB. The antitumor property of effector cells against the target cells (U87, TE671) were estimated using a visual survival cell assay. The mixed target and effector (UCB) cells were analyzed for whether DNA fragmentation was present or not. Reverse transcription polymerase chain reaction analysis was then performed to estimate the statement of the perforin and FasL genes in activated and inactivated cells from UCB. Results: The higher in vitro antitumor properties of the LAK cells from UCB were observed in comparison to the LAK cells from PB against the U87 and the TE671 (p<0.05). Apoptosis may be one of the lysis mechanisms of target cells by the LAK cells from UCB. The contributing genes could be FasL and perforin. Conclusions: This study suggests that UCB may be used as a source of LAK cells in adults and children suffering from anaplastic astrocytoma or medulloblastoma.

AB - Objects: The aims of this study were to assess the cytotoxic capability of lymphokine-activated killer (LAK) cells from umbilical cord blood (UCB), to compare them with those of peripheral blood (PB)-derived cells against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671), and to identify which mechanism and genes were involved in cytotoxicity. Methods: The effector cells were generated by interleukin-2 from UCB and PB. The antitumor property of effector cells against the target cells (U87, TE671) were estimated using a visual survival cell assay. The mixed target and effector (UCB) cells were analyzed for whether DNA fragmentation was present or not. Reverse transcription polymerase chain reaction analysis was then performed to estimate the statement of the perforin and FasL genes in activated and inactivated cells from UCB. Results: The higher in vitro antitumor properties of the LAK cells from UCB were observed in comparison to the LAK cells from PB against the U87 and the TE671 (p<0.05). Apoptosis may be one of the lysis mechanisms of target cells by the LAK cells from UCB. The contributing genes could be FasL and perforin. Conclusions: This study suggests that UCB may be used as a source of LAK cells in adults and children suffering from anaplastic astrocytoma or medulloblastoma.

UR - http://www.scopus.com/inward/record.url?scp=1842477504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842477504&partnerID=8YFLogxK

U2 - 10.1007/s00381-003-0898-7

DO - 10.1007/s00381-003-0898-7

M3 - Article

C2 - 14968374

AN - SCOPUS:1842477504

VL - 20

SP - 154

EP - 162

JO - Child's Nervous System

JF - Child's Nervous System

SN - 0256-7040

IS - 3

ER -